Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Xiang

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Prostate Cancer and Prostatic Diseases|March 25, 2023
Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern eraTing Martin Ma, Felix Y Feng, Seth A Rosenthal, et al.
Advances in Radiation Oncology|May 6, 2022
Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric ComparisonTrudy C Wu, Michael Xiang, Nicholas G Nickols, et al.
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.
Radiation Oncology (London, England)|May 21, 2020
Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volumeMichael S Binkley, Julie L Koenig, Mehr Kashyap, et al.
Neoplasia (New York, N.Y.)|November 26, 2019
CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3Susana P Egusquiaguirre, Suhu Liu, Isidora Tošić, et al.
Molecular Cancer Therapeutics|January 18, 2014
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2Suhu Liu, Sarah R Walker, Erik A Nelson, et al.
Nature Biotechnology|February 9, 2010
Ontology engineeringGil Alterovitz, Michael Xiang, David P Hill, et al.
Science Signaling|January 30, 2014
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypesMichael Xiang, Nicolai J Birkbak, Vida Vafaizadeh, et al.
JAMA Network Open|December 1, 2023
Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate CancerTing Martin Ma, Neeraj Agarwal, Brandon Mahal, et al.
Clinical Lung Cancer|December 8, 2023
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung CancerCaressa Hui, Cesar Marquez, Brianna Lau, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Prostate Cancer and Prostatic Diseases|March 25, 2023
Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern eraTing Martin Ma, Felix Y Feng, Seth A Rosenthal, et al.
Advances in Radiation Oncology|May 6, 2022
Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric ComparisonTrudy C Wu, Michael Xiang, Nicholas G Nickols, et al.
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.
Radiation Oncology (London, England)|May 21, 2020
Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volumeMichael S Binkley, Julie L Koenig, Mehr Kashyap, et al.
Neoplasia (New York, N.Y.)|November 26, 2019
CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3Susana P Egusquiaguirre, Suhu Liu, Isidora Tošić, et al.
Molecular Cancer Therapeutics|January 18, 2014
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2Suhu Liu, Sarah R Walker, Erik A Nelson, et al.
Nature Biotechnology|February 9, 2010
Ontology engineeringGil Alterovitz, Michael Xiang, David P Hill, et al.
Science Signaling|January 30, 2014
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypesMichael Xiang, Nicolai J Birkbak, Vida Vafaizadeh, et al.
JAMA Network Open|December 1, 2023
Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate CancerTing Martin Ma, Neeraj Agarwal, Brandon Mahal, et al.
Clinical Lung Cancer|December 8, 2023
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung CancerCaressa Hui, Cesar Marquez, Brianna Lau, et al.
Pageof 7